Current DED treatments, including lid hygiene, in-office procedures, and over-the-counter products, may help address MGD (meibomian gland dysfunction), a key upstream driver of excessive evaporation.3-6
Treatments may fall short in directly addressing tear
evaporation due to3-5:
Most Rx treatments leave excessive evaporation unaddressed.3,7-11
Anti-inflammatories and tear stimulators may be insufficient to resolve symptoms of DED, and low rates of compliance and adherence have been observed.12,13
In a retrospective insurance claim study of 6537 cyclosporine patients and 3235 lifitegrast patients,
Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye
Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting
Impact of dry eye disease on work productivity, and patients’ satisfaction with over-the-counter dry eye treatments
Sign up to stay informed about dry eye disease (DED), find out what your peers think about managing DED, and get updates about the advancements that Bausch + Lomb is pursuing.